Zentalis Pharmaceuticals (ZNTL)

• Market cap: $198M
• 1 day: 23.39%
• 5 days: 25.41%
• 1 month: 27.5%
• 3 months: 115.49%
• 6 months: 109.59%
• Year to date: 123.36%
• 1 year: 70.95%
• 5 years: -93.2%
• 10 years: -86.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166